Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized comparison of CNTO 1275 versus etanercept in moderate to severe plaque psoriasis
NL-OMON30775Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in plaque psoriasis comparing CNTO1275 arm with Etanercept arm (2 arms). Primary endpoint: PASI 75 response at week 12. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
ustekinumabetanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON30775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30775.